November 11-13, 2023 | Philadelphia, PA
Learn about the key features for plaque vulnerability.
Overview of the mechanism of LDL-C regulation and the role of PCSK9.
Summarized clinical recommendations on management of LDL-C in high-risk ASCVD patients.
Interact with a map showing cholesterol levels in high-risk CVD patients in your area.
Learn about real-world evidence in patients with ASCVD.
Learn more about atherosclerosis, opportunities to optimize management of ASCVD, and visit the NEW Shared Clinician/Patient Materials page.
Learn about the importance of recognizing elevated lipoprotein(a) in patients with ASCVD.
Learn about key features of vulnerable plaque and the imaging modalities that can be used to look at changes in plaque burden and composition.
ASCVD: Atherosclerotic cardiovascular disease, CVD: Cardiovascular disease, LDL-C: Low-density lipoprotein-cholesterol, PCSK9: Proprotein convertase subtilisin/kexin type 9